Perphenazine

Perphenazine
Clinical data
AHFS/Drugs.com	Monograph
MedlinePlus	a682165
Pregnancy; category	AU: C;
Routes of; administration	Oral and IM
Drug class	Typical antipsychotic
ATC code	N05AB03 (WHO) ;
Legal status
Legal status	BR: Class C1 (Other controlled substances); UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	40%
Metabolism	hepatic
Elimination half-life	8–12 (up to 20) hours
Identifiers
	IUPAC name 2-[4-[3-(2-chloro-10H-phenothiazin-10-yl) propyl]piperazin-1-yl]ethanol;
CAS Number	58-39-9 ;
PubChem CID	4748;
IUPHAR/BPS	209;
DrugBank	DB00850 ;
ChemSpider	4586 ;
UNII	FTA7XXY4EZ;
KEGG	D00503 ;
ChEBI	CHEBI:8028 ;
ChEMBL	ChEMBL567 ;
CompTox Dashboard (EPA)	DTXSID1023441 ;
ECHA InfoCard	100.000.346
Chemical and physical data
Formula	C21H26ClN3OS
Molar mass	403.97 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Clc2cc1N(c3c(Sc1cc2)cccc3)CCCN4CCN(CCO)CC4;
	InChI InChI=1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2 ; Key:RGCVKNLCSQQDEP-UHFFFAOYSA-N ;
	(verify)

Perphenazine is a typical antipsychotic drug. Chemically, it is classified as a piperazinyl phenothiazine. Originally marketed in the United States as Trilafon, it has been in clinical use for decades.

Perphenazine is roughly ten times as potent as chlorpromazine at the dopamine-2 (D2) receptor;^[2] thus perphenazine is considered a medium-potency antipsychotic.^[3]^[4]

^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
^ Rees L (August 1960). "Chlorpromazine and allied phenothiazine derivatives". British Medical Journal. 2 (5197): 522–5. doi:10.1136/bmj.2.5197.522. PMC 2097091. PMID 14436902.
^ Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J (February 2006). "Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia". BMC Psychiatry. 6 8. doi:10.1186/1471-244X-6-8. PMC 1402287. PMID 16504026.
^ Freudenreich O (2007). "Treatment of psychotic disorders". Psychotic disorders. Practical Guides in Psychiatry. Lippincott Williams & Wilkins. p. 88. ISBN 978-0-7817-8543-3. Retrieved 2009-06-22.

[1] Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.

[2] Rees L (August 1960). "Chlorpromazine and allied phenothiazine derivatives". British Medical Journal. 2 (5197): 522–5. doi:10.1136/bmj.2.5197.522. PMC 2097091. PMID 14436902.

[3] Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J (February 2006). "Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia". BMC Psychiatry. 6 8. doi:10.1186/1471-244X-6-8. PMC 1402287. PMID 16504026.

[Freu-4] Freudenreich O (2007). "Treatment of psychotic disorders". Psychotic disorders. Practical Guides in Psychiatry. Lippincott Williams & Wilkins. p. 88. ISBN 978-0-7817-8543-3. Retrieved 2009-06-22.

[1]

[2]

[3]

[4]